Arix Bioscience PLC Fundamentals Datasheet and Stock Analysis

Profile

Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.

Current Price:
162.50p
Industry:
Financials
Sector:
Financial Services
ISIN:
GB00BD045071
Market Sector:
MAIN
Main Indices:
N/A
Country of register:
Great Britain
Currency:
N/A
Shares in Issue:
135m
Market Cap:
£0m
Date Listed:
17/02/2017

Operation Breakdown

Geographical
Product

Geographical - by origin (turnover)

Product (turnover)

Loading...

Activity Data Not Available

Company Information

Non-Executive Director: veteran Arthur Pappas, Meghan FitzGerald Giles Kerr Non-Executive Chairman: Jonathan Peacock Senior Independent Non-Executive Director: Franz Bernhard Humer Chief Finance Officer: James Rawlingson Chief Executive Officer : Joseph Anderson Independent Non-Executive Director: Trevor Jones Chief Scientific Officer: Graeme Smith

Registrars:
Address:
20 Berkeley Square, London
Phone:
Website:
http://www.arixbioscience.com

Analysis

Composite Ranking: 66

Historic EPS Ranking: 35

Forecast EPS Ranking: 50

Price Relative Strength:

Industry Strength: A

SMR Ranking: D

ROCE Ranking: F

Accumulation/Dist: A

Mkt Accumulation/Dist: C

Unbroken Annual EPS: E

Unbroken Interim EPS: E

PEG Current Ranking: A

PEG Forecast Ranking: H

PE Current Ranking: A

PE Forecast Ranking: H

Margin Current Ranking: H

Margin Forecast Ranking: A

Chart

Log10 scale Add Indicator

Indicator

No of Periods

Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.

Fundamentals

Full Year
Interim
Q1
Q2
Q3
Q4

		2016	2017		2018E	2019E	2020E
Day/Month		31/12	31/12		31/12	31/12	31/12
Revenue	£m	0.64	1.86	£m	1.13	1.23	1.00
Operating Profit/(loss)	£m	(8.30)	(3.59)	£m	0.00	0.00	0.00
Profit Before Tax	£m	(9.53)	(7.69)	£m	47.25	53.40	41.60
Profit After Tax	£m	(8.84)	(7.47)	£m	0.00	0.00	0.00
Profit After Tax (from discontinued operations)	£m	0.00	0.00	£m	0.00	0.00	0.00
Overall Profit for the Period	£m	(8.84)	(7.47)	£m	0.00	0.00	0.00
EPS Growth	%	0.00	0.00	%	0.00	9.00	(35.00)
Earnings Per Share	p	(0.36)	(0.11)	p	0.34	0.37	0.24
Op. Cash Flow P/S	p	0.00	(11.16)	£	0.00	0.00	0.00
Cash Flow P/S Grth	%	0.00	0.00	%	0.00	0.00	0.00
Net Cash Flow P/S	p	0.00	0.00	£	0.00	0.00	0.00
Capital Exp P/S	£	0.00	0.00	£	0.00	0.00	0.00
Tax Rate	%	0.00	0.00	%	0.00	0.00	0.00
P/E Ratio	x	0.00	0.00	x	479.40	439.90	679.20
P/E Growth	£	0.00	0.00	£	0.00	49.00	(19.30)
Turnover Per Share	£	0.00	0.00	£	0.00	0.00	0.00
Pre-Tax Profit / Share	£	0.00	0.00	£	0.00	0.00	0.00
Operating Margin	%	(1,296.88)	(193.01)	%	0.00	0.00	0.00
ROCE	%	0.00	(8.73)	%	0.00	0.00	0.00
ROE	%	0.00	(7.75)	%	0.00	0.00	0.00
Mkt Cap	£m	0.00	262.91	£m	0.00	0.00	0.00
Dividend Per Share	p	0.00	0.00	p	0.00	0.00	0.00
DPS Growth	%	0.00	0.00	%	0.00	0.00	0.00
Dividend Yield	%	0.00	0.00	%	0.00	0.00	0.00
Dividend Cover	x	0.00	0.00	x	0.00	0.00	0.00
Shareholder Funds	£m	46.33	146.44	£m	0.00	0.00	0.00
Net Borrowings	£m	(28.93)	(74.94)	£m	0.00	0.00	0.00
Net Assets	£m	46.33	146.44	£m	0.00	0.00	0.00
Net Assets P/S	£	0.00	0.00	£	0.00	0.00	0.00

Financials

Income & Efficiency
Valuation
Growth

	Latest	Forecast
Div Yield	0.0%	0.0%
Div Cover	0.0%	0.0%
Op Margin	-193.0%	4,329.7%
ROCE	0.0%

Director Deals

Latest
Largest

Traded	Action	Notifier	Price	Amount	Value
20-Mar-18	Buy	Jonathan Peacock	225.00p	90,000	£,202,500
20-Mar-18	Buy	Jonathan Peacock	225.00p	90,000	£202,500
02-Jun-17	Buy	Joseph Anderson	2.06p	55,000	£113,355.01
02-Jun-17	Buy	Joseph Anderson	206.10p	55,000	£113,355.01
02-Jun-17	Buy	Jonathan Peacock	2.06p	28,016	£57,740.98
02-Jun-17	Buy	Jonathan Peacock	206.10p	28,016	£57,740.98
02-Jun-17	Buy	James Rawlingson	2.06p	26,000	£53,586
02-Jun-17	Buy	James Rawlingson	206.10p	26,000	£53,586
08-May-17	Buy	James Rawlingson	2.02p	11,484	£23,242.47
08-May-17	Buy	Jonathan Peacock	202.39p	11,484	£23,242.47

First Page Prev Page Next Page Rows per page

Shareholders

135m Major: 70% Director: 0%

Directors
Major Holders

Notifier	Holding	Value
Jonathan Peacock	129,500	Ð,495
Joseph Anderson	55,000	X,550
Giles Kerr	35,746	9,551.06
Meghan FitzGerald	35,545	9,227.45
James Rawlingson	26,000	),860

Rows per page

Gearing & Cover

News

Regulatory
Calendar Events
Activity

News Title	Date	Time	Source
Autolus announces updated results from CARPALL trial	19-Feb-19	12:12	PRN
Management and Board changes	19-Feb-19	07:00	PRN
Harpoon closes initial public offering	14-Feb-19	07:00	PRN
Harpoon prices Nasdaq IPO	08-Feb-19	07:09	PRN
Total Voting Rights	01-Feb-19	10:38	PRN
Update on Harpoon proposed IPO in the United States	29-Jan-19	14:25	PRN
Issue of Ordinary Shares and Total Voting Rights	03-Jan-19	07:00	PRN
Harpoon announces proposed public offering in the US	28-Dec-18	07:00	PRN
Arix appoints Dr Christian Schetter as EIR	11-Dec-18	07:00	PRN
Autolus presents initial AUTO3 clinical data at ASH	03-Dec-18	07:00	PRN

First Page Prev Page Next Page Rows per page

Broker Opinion

Latest
History
Views

Date	Broker Name	Rec	Price	Old Price Target	New Price Target	Broker Change